Wegovy and Heart Health: Is the Benefit About More Than Weight Loss?

Does Wegovy protect the heart simply because people lose weight?

We already know that excess weight is closely linked with cardiovascular risk. So when a weight-management treatment helps someone lose a significant amount of weight, it would be reasonable to assume that improvements in heart health happen mainly because of that weight loss.

New research suggests the story may be more complicated.

Researchers have published a new analysis of the large SELECT trial, looking at why semaglutide reduced serious cardiovascular events in people living with overweight or obesity and established cardiovascular disease.

What did SELECT originally show?

SELECT involved 17,604 adults aged 45 or over who had established cardiovascular disease and a BMI of at least 27 kg/m² but did not have diabetes.

Participants received either once-weekly injectable semaglutide, titrated towards 2.4 mg, or placebo.

The original study found that people receiving semaglutide had around a 20% lower risk of major cardiovascular events, including cardiovascular death, non-fatal heart attack or non-fatal stroke.

That evidence led the MHRA to approve Wegovy injection for cardiovascular risk reduction in appropriately selected adults with established cardiovascular disease.

What does the new research add?

Researchers wanted to know how much of that reduction in cardiovascular events could be explained by familiar improvements such as:

weight loss and smaller waist circumference;
lower blood pressure;
improvements in cholesterol and blood glucose;
reduced inflammation; and
improvements in kidney-related markers.

Semaglutide improved all of these measures.

However, when researchers analysed them together, they could not confidently explain the whole cardiovascular benefit seen with semaglutide.

This raises the possibility that other biological effects, potentially involving inflammation, blood-vessel function or the heart itself, may also contribute.

Does that mean Wegovy protects the heart even without weight loss?

Not quite.

This was a mediation analysis, which uses statistical modelling to explore possible explanations for a treatment effect. It cannot prove exactly which biological mechanism caused the reduction in cardiovascular events.

The estimates were also uncertain, with wide confidence intervals.

So the sensible interpretation is that weight loss alone does not appear to explain the complete picture, rather than claiming that weight loss does not matter.

Does this apply to Wegovy tablets?

We should also be careful here.

SELECT studied once-weekly injectable semaglutide, targeting 2.4 mg. It did not study the newer daily Wegovy tablet.

Although both contain semaglutide, cardiovascular outcome evidence from the injectable SELECT programme should not simply be assumed to apply identically to the tablet formulation.

Likewise, the newer 7.2 mg Wegovy injection dose has been authorised for weight management in adults with obesity, but the MHRA specifically states that this higher-dose approval does not apply to patients using Wegovy for cardiovascular-risk reduction.

Why this matters for weight management

The study is another reminder that modern obesity care should not be judged purely by the number on the scales.

Weight, waist circumference, blood pressure, metabolic health, cardiovascular risk, nutrition, mobility and long-term weight maintenance can all matter.

For some patients, the health benefits of successful treatment may therefore extend beyond simply achieving the lowest possible BMI.

How Pharmulous can help

At Pharmulous, weight-management treatment is reviewed on an individual basis rather than focusing on weight loss alone.

Our clinicians consider your medical history, cardiovascular and metabolic risk, previous treatment response, side effects, nutritional health and longer-term maintenance needs when discussing appropriate licensed weight-management options.

If you already have cardiovascular disease, treatment choice deserves particularly careful clinical assessment rather than simply selecting a medicine based on headline weight-loss percentages.